Literature DB >> 10956411

Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.

F A van den Brûle1, D Waltregny, F T Liu, V Castronovo.   

Abstract

Galectin-3, a member of the beta-galactoside-binding lectin family, is involved in a variety of biological events including interactions with galactose-containing glycoconjugates, cell proliferation, differentiation and apoptosis. Galectin-3 appears to intervene during tumor progression and altered expression patterns have been reported in a variety of malignancies. In our study, we have examined the expression of galectin-3 in a population of 145 prostate carcinoma samples using immunohistochemistry. We found that most of the non-tumoral prostatic glands exhibited moderate immunostaining for galectin-3 localized in both nucleus and cytoplasm. In prostatic cancer cells, galectin-3 was usually not expressed or decreased compared with the normal glands. Interestingly, when galectin-3 was detected in the cancer cells, it was consistently excluded from the nucleus and only present in the cytoplasmic compartment. The latter observation was also made for prostatic intraepithelial neoplasia (PIN) cells. Furthermore, we found that the levels of galectin-3 expression in the cancer cells were significantly associated with prostate-specific antigen (PSA) relapse in univariate analysis (p = 0.044). Cytoplasmic expression of galectin-3 in the carcinoma cells was an independent predictor of disease progression in multivariate analysis, after the pathological stage and the Gleason score. Our data demonstrate that galectin-3 is generally down-regulated in human prostate carcinoma cells, and consistently excluded from the nucleus. Interestingly, specific cytoplasmic expression of galectin-3 in a subset of lesions is associated with disease progression. These results suggest that galectin-3 might play anti-tumor activities when present in the nucleus, whereas it could favor tumor progression when expressed in the cytoplasm. Further studies should determine the exact role and mechanisms by which galectin-3 differentially affects cell behavior in the different locations where it is expressed. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10956411     DOI: 10.1002/1097-0215(20000720)89:4<361::aid-ijc8>3.0.co;2-u

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

Review 3.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

Review 4.  Why anti-Bcl-2 clinical trials fail: a solution.

Authors:  Y Harazono; K Nakajima; A Raz
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

5.  Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate.

Authors:  Jorge Luiz Araújo-Filho; Mário Ribeiro Melo-Junior; Eduardo Isidoro Carneiro Beltrão; Luiza Rayanna Amorim de Lima; Consuelo Barreto Lins Antunes; Luiz Bezerra de Carvalho
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

6.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

Review 7.  Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky
Journal:  J Am Coll Cardiol       Date:  2020-06-02       Impact factor: 24.094

8.  Regulation of prostate cancer progression by galectin-3.

Authors:  Yi Wang; Pratima Nangia-Makker; Larry Tait; Vitaly Balan; Victor Hogan; Kenneth J Pienta; Avraham Raz
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 9.  Dynamics of galectin-3 in the nucleus and cytoplasm.

Authors:  Kevin C Haudek; Kimberly J Spronk; Patricia G Voss; Ronald J Patterson; John L Wang; Eric J Arnoys
Journal:  Biochim Biophys Acta       Date:  2009-07-16

10.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.